title: Thrombolytic therapy in acute MI. Weighing the risks and benefits.
abstract: The underlying cause of acute myocardial infarction can now be effectively treated with thrombolytic agents, thereby increasing myocardial salvage and reducing mortality. Clinicians should always be aware of the risk-to-benefit ratio in treating patients with thrombolytic agents and treat each patient on an individual basis.
authors.affiliation: Department of Internal Medicine, University of Texas Health Science Center, Houston.
authors.forename: K G
authors.initials: KG
authors.lastname: Ro
authors.forename: H V
authors.initials: HV
authors.lastname: Anderson
mesh_terms: D000208:Acute Disease; D016255:Anistreplase / Q000008:administration & dosage; D001241:Aspirin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000075202:Contraindications; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D013300:Streptokinase / Q000008:administration & dosage; D015912:Thrombolytic Therapy; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage
chemical_list: D016255:Anistreplase; D006493:Heparin; D013300:Streptokinase; D010959:Tissue Plasminogen Activator; D001241:Aspirin